|
InsightMedi is a photosharing network for the healthcare industry – Instagram for doctors Founder: Juan González Source: DreamIT Health |
|
|
Artgen, Inc. is a biotechnology company developing breakthrough treatments for vascular diseases. The company has a pipeline of preclinical therapeutic candidates with the first product (Art101) developed for treatment of Peripheral Arterial Disease (PAD). Founders: Maxim Tvishor, Irena Tsyrlova BHI Lead Contact: Albine Martin Investment: Maryland Industral Partnerships (MIPS), Human Stem Cells Institute (Seed Investment) *BHI Cofounded Company |
|
|
Reduce risk and ensure patient trust with the #1 healthcare compliance analytics platform. Founder: Robert Lord Source: DreamIT Health |
|
|
miRNA for head and neck cancer Founder: Anthony Saleh BHI Lead Contact: Anthony Saleh Source: NIH |
|
Quantified Care is a remote monitoring and care-coordination platform Founder: Mike Batista Source: DreamIT Health |
|
|
Oral vaccines for the aquaculture industry Founder: Vik Vakharia Source: Institute of Marine and Environmental Technology (UMBC) |
|
|
Collaboration software for companies, institutions, and academia Founder: Chris Frew BHI Lead Contact: Judy Costello Source: DreamIT Health |
|
|
Mimetas is developing and marketing Organ-on-a-Chip solutions for the pharmaceutical industry Founder: Jos Joore / Paul Vulto BHI Lead Contact: Anthony Saleh Source: Netherlands / University of Leiden |
|
Juan Carlos Lopez of Roche and Mike Gill, Secretary for Maryland’s Department of Business and Economic Development, Join BHI Board
BioHealth Innovation, Inc. (BHI) announced today that its Board of Directors has unanimously voted and approved the appointments of Board Member Juan Carlos Lopez, Ph.D., Head of the Academic Relations and Collaborations (ARC) Group at Roche Pharma Research and Early Development (pRED), and Ex-Officio Board Member Mike Gill, Secretary, Department of Business and Economic Development (DBED), State of Maryland.
“We are pleased to have two powerhouse individuals join our dynamic board,” said Richard Bendis, BHI President and CEO. “We also want to thank Roche’s Dr. Judith Dunn for her commitment and service to our board during her tenure, which has now ended. We are grateful for her leadership and contributions during her time with us.”
Dr. Lopez leads the Roche pRED’s team in conducting outreach to academic and non-profit biomedical research and healthcare organizations for purposes of enhancing and complementing their internal R&D efforts. He began his career with the Nature Publishing Group in 2000, coming on board as an Associate Editor to launch Nature Reviews Neuroscience. In less than a year, he advanced to Chief Editor and led the publication to become the top monthly reviews journal in the neuroscience field, a position it retains to this day. In 2004, he was named Chief Editor at Nature Medicine, which is ranked by the Institute of Scientific Investigation as the world’s top journal in experimental and research medicine.